Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2574

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2574
---
. If we are unable to raise such capital when needed, or on acceptable
terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization
efforts and/or other operations.

Developing
biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain
process that takes years to complete. Our operations have consumed substantial amounts of cash since inception. We have sufficient committed
sources of additional capital to fund our operations for more than a limited period of time. We expect our expenses to increase in connection
with our ongoing activities, particularly as we advance our preclinical and clinical development programs, seek regulatory approvals
for our product candidates, and launch and commercialize any products for which we receive regulatory approval. We also expect to incur
additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in
order to maintain our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to
delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.

71

Our
actual capital requirements may vary significantly from what we expect, and we will in any event require additional capital in order
to complete clinical development of any of our current programs. Our monthly spending levels will vary based on new and ongoing development
and corporate activities. Because the length of time and the activities associated with development of our product candidates are highly
uncertain, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities. Our
future funding requirements, immediate, near and long-term, will depend on many factors, including, but not limited to:

    ●
    the
    initiation, progress, timing, costs and results of discovery, laboratory testing, manufacturing, preclinical studies and clinical
    trials for our current and future product candidates, including whether and when to advance our diverse portfolio of product candidates;

    ●
    the
    development requirements of other product candidates that we may pursue;

    ●
    the
    clinical development plans we establish for our product candidates;

    ●
    the
    timelines of our clinical trials and the overall costs to finish the clinical trials;

    ●
    the
    impact on timelines and costs due to unforeseen events;

    ●
    the
    number and characteristics of product candidates that we develop;